Nika Bagheri
Retina Specialist · Santa Barbara, CANPI 1790040087
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 64.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $22,269 and has fallen 99.2% since, to $168 in 2025.
Across 128 payments — averaging $570.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$47K
- Alcon Research LLC$8K
- Regeneron Healthcare Solutions, Inc.$6K
- Genentech, Inc.$5K
- Alcon$3K
- Carl Zeiss Meditec, Inc.$2K
- plus $2K from 11 others
Across 10 payments — averaging $45,537 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$424K
- Eyepoint US, Inc.$17K
- Regeneron$14K
What the payments were for
- Consulting fees$28,52839%
- Speaking & faculty fees$33,54046%
- Travel & lodging$4,5256%
- Food & beverage$4,2816%
- Gifts$2,1293%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 56 | $47,314 |
| Alcon Research LLC | 7 | $7,739 |
| Regeneron Healthcare Solutions, Inc. | 18 | $5,911 |
| Genentech, Inc. | 5 | $4,960 |
| Alcon | 3 | $2,960 |
| Carl Zeiss Meditec, Inc. | 2 | $2,199 |
| Thrombogenics, Inc. | 2 | $557 |
| Eyepoint US, Inc. | 4 | $358 |
| AbbVie(2 entities) | 13 | $280 |
| Alimera Sciences, Inc. | 8 | $141 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $139 |
| Novartis | 3 | $135 |
| Aerie Pharmaceuticals, Inc. | 1 | $125 |
| Sight Sciences, Inc. | 1 | $123 |
| Ocular Therapeutix, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Spark Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,003 in reported general payments places this provider in the 85th percentile of 187 retina specialist providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 22 | $704 |
| Ketorolac Tromethamine | 33 | $578 |
| Atropine Sulfate | 16 | $317 |
| MoxifloxacinMoxifloxacin Hcl | 18 | $202 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $148 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Santa Barbara
- Dilsher DhootSanta Barbara$1.9M
- Nathan SteinleSanta Barbara$1.1M
- Dante PieramiciSanta Barbara$267K
- Robert AverySanta Barbara$180K
- Daniel LearnedSanta Barbara$49K
- Stephen CouvillionSanta Barbara$43K
- Alessandro CastellarinSanta Barbara$24K
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Roger GoldbergWalnut Creek$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.